Quality of life during oral treatment for neuroendocrine tumors
Part of Cancer clinical trials.
This study looks at how well people with neuroendocrine tumors tolerate oral (pill) anti-cancer drugs and how these drugs affect their quality of life. It also tests a patient education program to help manage side effects and improve well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You have a neuroendocrine tumor (a rare type of tumor that can grow in the digestive tract, lungs, or other organs)
- Your doctor has prescribed an oral (pill) anti-cancer medication such as everolimus, sunitinib, cabozantinib, temozolomide (with or without capecitabine), or lenvatinib
- You are willing to participate and do not have any condition that prevents you from giving consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is tracking patients with advanced neuroendocrine tumors to see which treatments help them live longer without severe side effects, and how these side effects affect daily life. It aims to find the best treatment approaches for people like you.
This study follows people after surgery to remove neuroendocrine tumors (NETs) from the stomach, intestines, or pancreas. It aims to understand long-term outcomes and quality of life.
This study looks at how internal radiation therapy (RIV) affects quality of life in people with neuroendocrine tumors. It aims to understand how well patients tolerate this treatment and how it impacts daily life.
This study looks at how cancer and its treatment affect your eating and your quality of life related to food. By filling out questionnaires, you can help researchers understand your experience and potentially improve support for future patients.
This study follows patients who take oral anticancer drugs and take part in a special monitoring program at Lyon-Sud hospital. It aims to understand what affects treatment safety and outcomes.
This study asks people with neuroendocrine tumors to report how they’re doing, including quality of life and quality of care. Your answers can help doctors and hospitals understand what support works best.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.